What are the NCCN guidelines on the treatment of low-risk acute promyelocytic leukemia (APL)?

Updated: May 03, 2019
  • Author: Sandy D Kotiah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

For patients who are at low risk, NCCN lists the following regimens [14] :

  • All-trans-retinoic acid (ATRA), 45 mg/min divided doses daily until clinical remission, plus arsenic trioxide (ATO), 0.15 mg/kg IV daily until bone marrow remission (recommended)

  • ATRA plus daunorubicin (50 mg/m2 x 4 days or 60 mg/m2 x 3 days) and cytarabine (200 mg/m2 x 7 days)

  • ATRA plus idarubicin (12 mg/m2 on days 2, 4, 6, and 8)

  • ATRA plus ATO (0.3 mg/kg IV on days 1–5 of cycle one and 0.25 mg/kg twice weekly in weeks 2–8 or until clinical remission)

The NCCN recommends continuing induction therapy until count recovery occurs, then proceeding to consolidation therapy. 

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!